Darier Disease Complicated by Terbinafine-resistant Trichophyton rubrum
A Case Report
Digby, Sanna S; Hald, Marianne; Arendrup, Maiken C; Hjort, Sofie V; Kofoed, Kristian

Published in:
Acta Dermatovenereologica

DOI:
10.2340/00015555-2455

Publication date:
2017

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY-NC

Citation for published version (APA):
Digby, S. S., Hald, M., Arendrup, M. C., Hjort, S. V., & Kofoed, K. (2017). Darier Disease Complicated by Terbinafine-resistant Trichophyton rubrum: A Case Report. Acta Dermatovenereologica, 97(1), 139-140. https://doi.org/10.2340/00015555-2455
Trichophyton rubrum (T. rubrum) is the most common cause of superficial dermatomycoses worldwide and is responsible for more than 70% of all dermatophyte infections (1). T. rubrum infections can be long-lasting, difficult to treat and commonly recur after cessation of antifungal therapy (2). Unsuccessful treatment may be due to re-infection and poor adherence. Recurrence is seldom thought to be associated with resistance to antifungal agents and only a few cases of T. rubrum resistance to terbinafine have been reported (3). We report here a case of a patient with severe worsening of Darier disease (DD) due to widespread cutaneous terbinafine-resistant T. rubrum infection.

CASE REPORT

A 62-year-old man with DD was referred for evaluation due to a flare-up of his skin condition. The patient had experienced skin changes of fluctuating severity since the age of 12 years. His father was also known to have DD. Over the years he had consulted several dermatologists and been prescribed various topical agents and systemic acitretin, with little or no effect. In addition, he underwent numerous topical and systemic treatments for flare-ups due to recurrent fungal, bacterial and viral skin infections. At initial presentation to our clinic, besides usual keratotic follicular papules, several well-defined erythematous annular scaly plaques were observed on the trunk and extremities (Fig. 1), indicating tinea corporis, although the patient had recently taken oral terbinafine for months.

Skin scraping was performed and direct microscopy revealed septate hyphae and arthroconidia. Culture on Sabouraud agar supplemented with cycloheximide, and direct PCR were positive for T. rubrum, as described previously (4). A skin biopsy, in addition to acantholysis typical of DD (Fig. 2a) showed fungal spores and hyphae within the stratum corneum (Fig. 2b). Over the course of the next 4 months treatment with topical antifungal, 2 × 30-day courses of oral terbinafine (250 mg daily) and various topical corticosteroids failed to improve the patient’s skin condition.

Due to the continued presentation of tinea corporis, fungal analyses were repeated and supplemented with antifungal susceptibility testing according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) micro-dilution reference method E.Def 9.3 with C. krusei ATCC6258 as control strain (5). This revealed the T. rubrum isolate to be resistant to terbinafine (minimum inhibitory concentration (MIC) > 4 µg/ml), but susceptible to itraconazole (MIC 0.03 µg/ml). A randomly selected clinical T. rubrum isolate was found sensitive to both drugs (terbinafine MIC: 0.25 µg/ml, and itraconazole MIC ≤ 0.03 µg/ml). Two weeks after treatment with oral itraconazole (100 mg twice daily) the patient showed a dramatic improvement, the round skin lesions had cleared and his DD settled (see Fig. 1).

DISCUSSION

DD is a rare genodermatosis characterized by persistent, greasy, hyperkeratotic
Papules in seborrhoeic areas of the face, scalp and chest. These papules may coalesce and form larger warty malodorous lesions, especially within skin folds. Pruritus and nail changes are also a common symptom. The onset of symptoms usually occurs in adolescence and may be exacerbated by heat, ultraviolet B (UVB) light and mechanical trauma. Flares of DD may also be brought on by secondary skin infections (6). Although there are only a few reports, it is generally thought that patients have a predisposition to secondary bacterial, viral and fungal infections, due to compromised skin integrity (7, 8).

The case reported here illustrates a patient with severe DD complicated by *T. rubrum* infection, refractory to treatment until the dermatophyte infection was cleared. Terbinafine is often the antifungal agent of choice when treating dermatophytes (9). It is a synthetic allyl amine derivative that inhibits squalene epoxidase, blocking the biosynthesis of ergosterol (an essential component of fungal cell membranes) and resulting in the accumulation of toxic levels of squalene (2, 3, 9).

Drug resistance in dermatophytes is rare and, to our knowledge, only one case of terbinafine-resistant *T. rubrum* has been published (9). In the literature the proposed mechanism of acquired resistance is modification of the target enzyme by gene mutation and an increase in drug efflux; less frequently, intrinsic characteristics of a *T. rubrum* strain may play a role (2, 3). In our case it was more likely acquired as a result of prolonged terbinafine therapy.

With an increasing incidence of dermatophytosis, it is important to consider antifungal drug resistance as a cause of treatment failure.

The authors declare no conflicts of interest.

**REFERENCES**

1. Drakensjö IT, Chryssanthou E. Epidemiology of dermatophyte infections in Stockholm, Sweden: a retrospective study from 2005–2009. Med Mycol 2011; 49: 484–488.
2. Ghelardi E, Celandroni F, Gueye SA, Salvetti S, Senesi S, Bulgheroni A, et al. Potential of ergosterol synthesis inhibitors to cause resistance or cross-resistance in trichophyton rubrum. Antimicrob Agents Chemother 2014; 58: 2825–2829.
3. Mukherjee PK, Leidich SD, Isham N, Leitner I, Tyler NS, Ghannoum MA. Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother 2003; 47: 82–86.
4. Brillowska-Dabrowska A, Nielsen SS, Nielsen HV, Arendrup MC. Optimised 5-hour multiplex PCR test for the detection of tine unguium: performance in routine PCR laboratory. Med Mycol 2010; 48: 828–831.
5. Arendrup MC, Meletiadis J, Mouton JW, Guinea J, Cuenca-Estrella M, Lagrou K, et al. EUCAST Technical Note on Aspergillus and isavuconazole, Candida and itraconazole and updates for the method documents. Clin Microbiol Infect 2016; 22: 571.e1–4.
6. Engin B, Kutlubay Z, Erkan E, Tüzün Y. Darier disease: A fold (intertriginous) dermatosis. Clin Dermatol 2015; 33: 448–451.
7. Sehgal VN, Srivastava G. Darier’s (Darier-White) disease/keratosis follicularis. Int J Dermatol 2005; 44: 184–192.
8. Nenoff P, Krüger C, Ginter-Hanselmayer G, Tietz H. Mycology – an update. Part 1: Dermatomycoses: causative agents, epidemiology and pathogenesis. J Dtsch Dermatol Ges 2014; 12: 188–209.
9. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008; 166: 353–367.